Torre-Amione Guillermo, Orrego Carlos M, Khalil Nashwa, Kottner-Assad Christian, Leveque Christopher, Celis Rene, Youker Keith A, Estep Jerry D
Methodist DeBakey Heart and Vascular Center, The Methodist Hospital, Houston, Texas, USA.
J Clin Apher. 2010;25(6):323-30. doi: 10.1002/jca.20264. Epub 2010 Sep 24.
Previous reports had emphasized the importance of humoral immunity in heart failure in humans, primarily determined by the presence of circulating antibodies. However, there is little or no information about the frequency of anticardiac antibodies present in failing human myocardium.
Clinical data and myocardial tissue samples were analyzed to determine the role of humoral immunity in patients with chronic heart failure (CHF) in different SETTINGS.
Anticardiac antibodies were found present in failing hearts but not in normal control hearts. Further, the level of expression of these anticardiac antibodies changed with the severity of the disease state; and in patients with acute heart failure, we found selective activation of B cells. Finally, treatment of CHF patients with therapeutic plasma exchange, a strategy that removes circulating antibodies, resulted in a reduction in anticardiac antibody deposition and improvements in cardiac function.
These data collectively suggest a role of humoral immunity in the progression of heart failure.
既往报告强调了体液免疫在人类心力衰竭中的重要性,主要由循环抗体的存在所决定。然而,关于衰竭的人类心肌中抗心脏抗体的频率,几乎没有相关信息。
分析临床数据和心肌组织样本,以确定体液免疫在不同情况下慢性心力衰竭(CHF)患者中的作用。
在衰竭心脏中发现了抗心脏抗体,而正常对照心脏中未发现。此外,这些抗心脏抗体的表达水平随疾病状态的严重程度而变化;在急性心力衰竭患者中,我们发现B细胞有选择性激活。最后,用治疗性血浆置换(一种去除循环抗体的策略)治疗CHF患者,导致抗心脏抗体沉积减少,心脏功能改善。
这些数据共同表明体液免疫在心力衰竭进展中起作用。